CD274 and lung carcinoma: Immunotherapy with Immune Checkpoint Inhibitors (ICIs) has shown promising therapeutic effects in the treatment of lung cancer, the overall efficacy of PD‐1/PD‐L1 inhibitors is only 20%‐30%.